AlloMek Therapeutics

AlloMek Therapeutics, LLC is a private company focused on orphan diseases, developing treatments for catastrophic cardiomyopathy caused by LMNA gene mutations (Laminopathies) (based on discoveries from Dr. Worman's group) and congenital muscular diseases, dedicated to creating innovative therapies for patients with rare and debilitating conditions. AlloMek’s lead compound, CIP-137401, is a unique, proprietary macrocyclic small-molecule MEK kinase inhibitor that could potentially be used as a standalone drug and in combination with other therapeutic regimens to enhance clinical responses.